Çocuk ve genç kanser hastalarýnda kemoterapi ile birlikte bölgesel hipertermi uygulamasý

Çocuk ve genç kanser hastalarýnda kemoterapi ile birlikte bölgesel hipertermi uygulamasý

Çocuk ve genç kanser hastalarýnda kemoterapi ile birlikte bölgesel hipertermi uygulamasý

 

Regional hyperthermia combined with chemotherapy in paediatric, adolescent and young adult patients: current and future perspectives.

 

Radiat Oncol. 2016 Apr 30;11:65. doi: 10.1186/s13014-016-0639-1.

 

Seifert G¹, Budach V², Keilholz U³, Wust P², Eggert A⁴, Ghadjar P².

Author information

• ¹Department of Paediatric Oncology and Haematology, Otto-Heubner Centrum für Kinder- und Jugendmedizin, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany. georg.seifert@charite.de.
• ²Department of Radiation Oncology, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
• ³Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Virchowweg 23, 10115, Berlin, Germany.
• ⁴Department of Paediatric Oncology and Haematology, Otto-Heubner Centrum für Kinder- und Jugendmedizin, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.

Abstract

Here we evaluate the current status of clinical research on regional hyperthermia (RHT) in combination with chemotherapy or radiation therapy in paediatric oncology.Data were identified in searches of MEDLINE, Current Contents, PubMed, and references from relevant articles using medical subject headings including hyperthermia, cancer, paediatric oncology, children, radiation therapy and chemotherapy. Currently, only two RHT centres exist in Europe which treat children. Clinical RHT research in paediatric oncology has as yet been limited to children with sarcomas and germ cell tumours that respond poorly to or recur after chemotherapy. RHT is a safe and effective treatment delivering local thermic effects, which may also stimulate immunological processes via heat-shock protein reactions. RHT is used chiefly in children and adolescents with sarcomas or germ cell tumours located in the abdomino-pelvic region, chest wall or extremities to improve operability or render the tumour operable. It could potentially be combined with radiation therapy in a post-operative R1 setting where more radical surgery is not possible or combined with chemotherapy instead of radiation therapy in cases where the necessary radiation dose is impossible to achieve or would have mutilating consequences. RHT might also be an option for chemotherapy intensification in the neoadjuvant first-line treatment setting for children and adolescents, as was recently reflected in the promising long-term outcome data in adults with high-risk soft tissue sarcomas (EORTC 62961/ESHO trial).The limited data available indicate that combining RHT with chemotherapy is a promising option to treat germ cell tumours and, potentially, sarcomas. RHT may also be beneficial in first-line therapy in children, adolescents and young adults. The research should focus on optimising necessary technical demands and then initiate several clinical trials incorporating RHT into interdisciplinary treatment of children, adolescents and young adults that include translational research components exploring potential immunological mechanisms of action.